Avivagen Inc. Completes Private Placement

Friday, 29 June 2012 08:00 AM

OTTAWA, ONTARIO, June 29, 2012 -Avivagen Inc. (TSX Venture Exchange: VIV), today announced that it has issued a total of 1,429,000 common shares and an equal number of common share purchase warrants for gross proceeds of $100,030 through a non-brokered private placement.

This private placement involved the sale of units, each comprised of one common share and one common share purchase warrant, for a unit price of $0.07. Each warrant entitles the holder to acquire one common share of Avivagen at an additional purchase price of $0.10 per share for three years from closing.

The net proceeds of the proposed offering will be used to fund working capital and research and development expenditures and for general corporate purposes.

The securities issued under this private placement are and will be subject to restrictions on transfer, including a hold period ending four months after issuance. The private placement remains subject to TSX Venture Exchange approval. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities.

About Avivagen

Avivagen, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com and www.chemaphor.com.

For more information:

David HankinsonGraham Burton, PhD

CEO, Avivagen Inc.President and Co-Founder, Avivagen Inc.

Phone: 902-825-9270Phone: 613-990-0969

[email protected]@avivagen.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

-